Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML - ScienceDirect
Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis | PLOS ONE
Overalls | TERWIJN ZWOLLE BEDRIJFSKLEDING
TERWIJN ZWOLLE BEDRIJFSKLEDING | Werkkleding en meer
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka
A new class of leaders | Article | The United States Army
The Evolving Treatment Landscape of AML | Published in healthbook TIMES Oncology Hematology
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS - ScienceDirect
Overalls | TERWIJN ZWOLLE BEDRIJFSKLEDING
Overalls | TERWIJN ZWOLLE BEDRIJFSKLEDING
Overalls | TERWIJN ZWOLLE BEDRIJFSKLEDING
The Evolving Treatment Landscape of AML | Published in healthbook TIMES Oncology Hematology
Unified classification and risk-stratification in Acute Myeloid Leukemia | Nature Communications
A new class of leaders | Article | The United States Army
The Evolving Treatment Landscape of AML | Published in healthbook TIMES Oncology Hematology
Cancers | Free Full-Text | Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine